Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 5.65%
As of Thursday, July 30, Cardiol Therapeutics Inc.’s CRDL share price has surged by 5.65%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Commentary & Analysis
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 5.28%
As of Friday, July 24, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 7.21%
As of Thursday, July 16, Cardiol Therapeutics Inc.’s CRDL share price has surged by 7.21%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Up 13.06%
As of Thursday, July 16, Cardiol Therapeutics Inc.’s CRDL share price has surged by 13.06%, which has investors questioning if this is right time to sell.Tudor Pop
Why Cardiol Therapeutics Inc.’s (CRDL) Stock Is Down 5.22%
As of Wednesday, July 15, Cardiol Therapeutics Inc.’s CRDL share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $144.7 | $579.1 | 25% |
|
| Shares Out (Mil) | 78.1 | 43.0 | 57% |
|
| Institutional Ownership | 78.8% | 84.3% | 48% |
|
| Float (Mil) | 96.5 | 46.8 | 61% |
|
| Beta | 0.48 | 0.62 | 27% |
|
| Avg Daily Volume (000s) | 828 | 285 | 67% |
|
| Price Change (52-week) |
(14.2%) | 63.8% | 34% |
|
| Growth | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (8.8%) | (1.4%) | 30% |
|
| EPS (5yr) | 12.2% | 14.9% | 50 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (19.7%) | (14.9%) | 34% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 3 | |
| Current EPS | ($0.069) | ($0.257) | ($0.200) | |
| Month Ago EPS | ($0.069) | ($0.257) | ($0.200) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.064) | ($0.268) | ($0.169) | |
| Year/Year Chg | (2.8%) | (9.5%) | (109.2%) | |
| Financials | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($26) | ($11) | 21% |
|
| EPS (TTM) | ($0.278) | ($0.500) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $3 | $4 | 51% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 10% |
|
| Enterprise Value (Q1) (Mil) | $105 | $522 | 21% |
|
| Valuation | CRDL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.47 | 2.73 | 88% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CRDL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (129.5%) | (24.6%) | 4% |
|
| ROE | (176.1%) | (19.7%) | 5% |
|
| Liabilities to Assets | 22.9% | 35.5% | 15% |
|
| F-Score | 2 | 3 | 7% |
|
Cardiol Therapeutics Inc. did not pass any screens on 7/31/2026.
